Policies for helping smokers who cannot quit: a prerequisite for maximum prevention of tobacco induced diseases Lars M. Ramström Institute for Tobacco.

Slides:



Advertisements
Similar presentations
NC STEP/Mission Hospitals School Cessation and Treatment Guide.
Advertisements

A Clinical Flow-Chart for the “Treatment-Resistant Smoker”
Quitting smoking is always the best option, however, some smokers are not yet ready or willing to quit and continue to inflict harm on themselves and the.
New Tobacco Products: Harm Reduction or Harm Induction? Herbert H. Severson Senior Research Scientist Oregon Research Institute Eugene, Oregon.
Reducing the toll of smoking-related disease and death: The case for tobacco harm reduction The rationale for establishing low-toxicity smokeless nicotine.
Tobacco & Cancer. Tobacco Use And Cancer Tobacco use, the most preventable cause of death in our society, accounts for at least 30% of all cancer deaths.
UNIVERSITY OF MARYLAND SCHOOL OF LAW The Basis of a Comprehensive Regulatory Policy for Reduced Harm Tobacco Products David Sweanor, Adjunct Professor.
In the name of GOD Decreasing smoking behavior and risk through CYP2A6 inhibition Shadi Sarahroodi (Pharm.D) Ahvaz Jondishapour University of medical.
Smoking and mental health Mark Allen Specialist Health Improvement Practitioner.
《 Promotion of Capability and Effectiveness for Tobacco Control Program among Rural Residents* 》 --Report On The Baseline Survey (Tobacco use status among.
Dejar de Fumar Hoy - Quit Smoking Now: A Smoking Cessation Program for Latinos Sally Haack, Pharm.D., BCPS; Naomi Barasch, Pharm.D. Candidate Drake University.
Concurrent Tobacco Use: A Study of Socio-demographic Correlates Nasir Mushtaq, MPH Laura A Beebe, PhD University of Oklahoma Health Sciences Center.
Who tries how? Quit attempts among Swedish smokers Lars M. Ramström Institute for tobacco studies Stockholm, Sweden 6th Annual Conference of the SRNT Europe.
Prevention strategies
Smoking Cessation. Opportunity for Physicians 70 percent of smokers want to quit. Without assistance only 5 percent are able to quit. Most try to quit.
Chewing tobacco By: Nick and Josh.
HEAPHY 1 & 2 DIAGNOSTIC James HAYES Fri 30 th Aug 2013 Session 2 / Talk 4 11:33 – 12:00 ABSTRACT To estimate population attributable risks for modifiable.
Establish and Sustain Tobacco Cessation Programs
Kenneth E. Warner University of Michigan University of Iowa November 15, 2002 Technology, Policy, and the Future of Nicotine Addiction.
Current challenges in tobacco prevention – do new products pose threats or opportunities? Lars M. Ramström Institute for Tobacco Studies Stockholm, Sweden.
Evidence-based/Best Practices Tobacco Control Hadii Mamudu, PhD, MPA COPH-China Institute November 17, 2011.
Clinical aspects of smoking cessation Jean-Pierre Zellweger, MD Swiss Lung Association and Int. Union against TB and Lung Disease (The Union)
Snus as a Substitution for Smoking: The Swedish Experience Lars M. Ramström Institute for tobacco studies Stockholm, Sweden.
Quitting Cigarettes Completely or Switching to Smokeless Tobacco: Do U.S. Data Replicate the Swedish Results? Shu-Hong Zhu University of California, San.
Rene Maximiliano Gomez, MD Head, Allergy & Asthma Unit Hospital San Bernardo, Salta - Argentina.
TOBACCO. What is it? An agricultural crop Also known as “chew” “dip” “smoke” Can be smoked, chewed, dipped and spit out Brown cut up leaves Main ingredient.
Le rôle de la réduction de dommages dans la lutte antitabac The role of harm reduction in tobacco control Lars M. Ramström Institute for Tobacco Studies.
TOBACCO PREVENTION AND CONTROL PROGRAM Mike Maples, Assistant Commissioner Mental Health and Substance Abuse Services.
Department of Medicine. The Harm Reduction Debate Current context of the debate - Snus enthusiasts vs. pessimists Switching from cigarettes to snus alone.
Characteristics of new tobacco products emerging on the tobacco market: implications for tobacco control policies Lars M. Ramström Institute for Tobacco.
Smoking cessation aided by low-toxicity smokeless tobacco can save many lives Lars M. Ramström Institute for Tobacco Studies Täby, Sweden UKNSCC 2014 Thursday.
Saving Smokers’ Lives: Evidence Based Strategies Joel L. Nitzkin, MD at AAPHP Session at AMA HOD Chicago, Ill June 15, 2013 June 15, 2013 AAPHP at AMA.
Tobacco Lesson 2. Canadian Tobacco Use Monitoring Survey (CTUMS) Indicates that smoking rates among teens have fallen in recent years. Indicates that.
Number of deaths (’000s) in 1998 attributable to tobacco use WHO Region Males Females World Health Report 1999 All member states3, Africa 112.
Tobacco Use. Cigarette Smoke Cigarettes Contain 4000 different chemicals Contain 43 known carcinogens Cyanide, formaldehyde, and arsenic Also contain.
Prospective Studies (cohort, longitudinal, incidence studies) Sue Lindsay, Ph.D., MSW, MPH Division of Epidemiology and Biostatistics Institute for Public.
Changes in Patterns of Substance Use ─ Tobacco Lars Ramström Institute for Tobacco Studies Stockholm, Sweden 49th International ICAA Conference on Dependencies.
Increasing Access to Pharmacotherapy Jonathan P. Winickoff, MD, MPH Associate Professor in Pediatrics Harvard Medical School April 26, 2013.
Cutting tobacco’s death toll − an overview of different options Lars M. Ramström Institute for Tobacco Studies Stockholm, Sweden 5th Annual Conference.
Prepared by: Dr. Mohammad Shaikhani University of Sulaimani College of Medicine. Dept of Medicine.
Lars M. Ramström PhD Director, Institute for Tobacco Studies Stockholm, Sweden The Swedish experience the role.
Early interest focused on pseudo-cigarettes. Why? Fascination with high-tech products First “splash” (Premier, mid-1980s) Promised large decreases in a.
The Role of Harm Reduction in Tobacco control – An Update of Pros and Cons Lars M. Ramström Institute for Tobacco Studies Stockholm, Sweden 53rd International.
By: Nancy Casimir, Tenecia Gaines, Shayna Knowles, & Sherrita Perry.
Living Tobacco-Free It really is possible!. Agenda Statistics and mortality risks Health risks Benefits of quitting Ways to quit.
The e-cigarette: opportunity or threat? SSA Annual Symposium 2015 Deborah Arnott Chief Executive Action on Smoking and Health.
Quitting smoking is always the best option however, some smokers are not yet ready or willing to quit and continue to inflict harm on themselves and the.
Population prevalence of disease risk factors and economic consequences for the healthcare system - possible scenarios Inna Feldman Uppsala University.
Key prevalence data, Sweden (Source: ITS/FSI study 2001/2002) MALES FEMALES (n=3205) (n=3507) Daily Daily Daily Daily smoking snus use smoking snus use.
Trends in electronic cigarette use in England Robert West Emma Beard Jamie Brown University College London
1 Access to and use of aids to smoking cessation in the UK Robert West University College London Austin, Texas February 2007.
Smoking in England Robert West Jamie Brown University College London 1.
Cigarette Smoking Chinauwa Howard HWE200: Introduction to Health and Wellness Instructor: Dr. Mileski April 25, 2016 Know the Risk.
Addressing Tobacco Use in Medical Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester School.
1 Tobacco smoking: where are we now and what can be done to reduce prevalence? Robert West University College London Cardiff, April 2008.
INFLUENCE OF TOBACCO AND PHARMACEUTICAL INDUSTRIES ON TOBACCO CONTROL PROGRAMS John P. Pierce, Wael Al-Delaimy Karen Messer, Dennis Trinidad & UCSD Tobacco.
Potential Reduced Exposure Products (PREPs) for Tobacco Users: What Are They and What Do They Do ? Thomas Eissenberg, Ph.D. Department of Psychology and.
Tobacco Use.
6 myths and facts about tobacco use disorder in people with mental health and substance use disorders Associate Professor.
Why and How to Quit Smoking
The case for raising the minimum age for tobacco use.
Tobacco Cessation Guidelines for COPD
The Burden of Tobacco Use
Griffith Health Institute
Trends in use of electronic cigarettes in England
Tobacco Road Takes a Turn to the Smokeless
Local Tobacco Control Profiles The webinar will start at 1pm
ELECTRONIC CIGARETTES WHAT’S THE BOTTOM LINE?
a specific MRTP ─ Snus ─ a low-toxicity oral tobacco product.
Choosing to Live Tobacco Free
Presentation transcript:

Policies for helping smokers who cannot quit: a prerequisite for maximum prevention of tobacco induced diseases Lars M. Ramström Institute for Tobacco Studies Stockholm, Sweden 7th Annual Conference of ISPTID, Kyoto, Japan, September, 2008

Overall goal for tobacco control: Maximum prevention of tobacco induced diseases This goal includes intermediate objectives concerning measures to help specific target groups such as:  Never tobacco users  Current tobacco users

Objective of measures to help never-tobacco-users: Preventing onset of tobacco use Strength:  In individuals for whom these measures have been successful, tobacco induced diseases will not occur Weaknesses:  Measures to prevent onset of tobacco use have limited success rate  Even when successful: Virtually no reduction of disease in nearest 30–40 years

#1 objective of measures to help current tobacco users: Quitting all tobacco/nicotine use Strength:  Disease risks decreasing substantially, eventually approaching never-user levels Weaknesses:  Treatments in clinical settings reach a limited fraction of smokers and have limited success rate  Quit attempts made outside clinical settings (the majority of all) get no or inadequate support

Occurrence of quit attempts in Sweden (% of all ever daily smokers) Men Women  Not made any quit attempt 9% 8%  Made one or more quit attempts - but do still smoke 36%47% - and have quit completely55%45% Source: ITS/FSI surveys of the Swedish population

”Do still smoke” after latest quit attempt by level of nicotine dependence Men Women  Low nicotine dependence 34% 36%  Medium nicotine dependence 40%56%  High nicotine dependence 56% 66% Source: ITS/FSI surveys of the Swedish population

Main area #4 Helping those who cannot quit: considering the potential of a harm reduction approach in tobacco control to help people whose addiction to nicotine makes it extremely difficult to quit altogether.

 People smoke because they are addicted to nicotine, but nicotine itself is not especially hazardous; it is the other constituents of tobacco smoke that cause most of the harm.  Use of smoke-free nicotine would benefit smokers directly by reducing the personal harm caused by nicotine addiction What is harm reduction, and how would it work for smoking? Excerpts from: Ending tobacco smoking in Britain; Radical strategies for prevention and harm reduction in nicotine addiction, Royal College of Physicians of London, 2008.

 The safest form of nicotine is medicinal or ‘pure’ nicotine, such as that contained in nicotine replacement therapy (NRT) products including skin patches and chewing gum.  However, although helpful, few smokers find NRT to be a satisfying alternative to smoking What is the safest way to provide nicotine without smoke? Excerpts from: Ending tobacco smoking in Britain; Radical strategies for prevention and harm reduction in nicotine addiction, Royal College of Physicians of London, 2008.

 Nicotine can also be obtained without smoke from a range of tobacco products, usually referred to as ‘smokeless’ tobacco.  In Sweden, the availability and use by men of an oral tobacco product called snus, one of the less hazardous smokeless tobacco products, is widely recognised to have contributed to the low prevalence of smoking in Swedish men and consequent low rates of lung cancer.  All smokeless tobacco products are therefore more hazardous than medicinal nicotine, and in some cases especially so, but all are also substantially less hazardous than smoking. What are the alternatives to medicinal nicotine? Excerpts from: Ending tobacco smoking in Britain; Radical strategies for prevention and harm reduction in nicotine addiction, Royal College of Physicians of London, 2008.

#2 objective of measures to help current tobacco users Switching to a nicotine product that is markedly less harmful Strengths:  Realistic alternative even for highly nicotine dependent people  Disease risks potentially decreasing almost as much as when quitting Weaknesses:  Continued exposure to nicotine  Maintenence of nicotine dependence  Limited availability of appropriate products

Summary and conclusions (1) Primary prevention policies are important - but not enough Smoking cessation policies are important - but not enough

Summary and conclusions (2) In order to prevent largest possible number of potentially preventable cases of tobacco induced diseases there is a need for policies helping those smokers who cannot quit to find less harmful alternatives, such as medicinal nicotine or low risk types of smokeless tobacco.